Evosep
@evosep.bsky.social
Our technology combine user-friendly workflows with automated processes. It empowers researchers, even without extensive expertise, to confidently use liquid chromatography mass spectrometry based proteomics in their work.
A special thank you to EIFO and Novo Holdings for their invaluable support throughout our journey so far. Your backing has been instrumental in bringing us to this point.
Now, let’s shape the future of proteomics.
#proteomics #healthcare #partnership #LCMS #biotech
Now, let’s shape the future of proteomics.
#proteomics #healthcare #partnership #LCMS #biotech
November 18, 2025 at 12:01 PM
A special thank you to EIFO and Novo Holdings for their invaluable support throughout our journey so far. Your backing has been instrumental in bringing us to this point.
Now, let’s shape the future of proteomics.
#proteomics #healthcare #partnership #LCMS #biotech
Now, let’s shape the future of proteomics.
#proteomics #healthcare #partnership #LCMS #biotech
With Nordic Capital’s proven track record in healthcare and technology, we are ready to accelerate innovation, expand globally, and deliver transformative solutions for researchers and clinicians.
November 18, 2025 at 12:01 PM
With Nordic Capital’s proven track record in healthcare and technology, we are ready to accelerate innovation, expand globally, and deliver transformative solutions for researchers and clinicians.
Together, we aim to redefine how proteomics drives efficiency, quality, and insight across healthcare and life sciences. Evosep’s mission remains set in stone, and customers can expect us to continue pushing forward the standardization of LCMS-based proteomics with impactful products and solutions.”
November 18, 2025 at 12:01 PM
Together, we aim to redefine how proteomics drives efficiency, quality, and insight across healthcare and life sciences. Evosep’s mission remains set in stone, and customers can expect us to continue pushing forward the standardization of LCMS-based proteomics with impactful products and solutions.”
As our CEO, Morten Bern, shares:
“Nordic Capital has great expertise across biopharma, medtech and diagnostics, and we are thrilled to have them onboard as Evosep is moving into the next growth phase.
“Nordic Capital has great expertise across biopharma, medtech and diagnostics, and we are thrilled to have them onboard as Evosep is moving into the next growth phase.
November 18, 2025 at 12:01 PM
As our CEO, Morten Bern, shares:
“Nordic Capital has great expertise across biopharma, medtech and diagnostics, and we are thrilled to have them onboard as Evosep is moving into the next growth phase.
“Nordic Capital has great expertise across biopharma, medtech and diagnostics, and we are thrilled to have them onboard as Evosep is moving into the next growth phase.